2019冠状病毒病患者的皮肤色素沉着：多粘菌素B是罪魁祸首吗？ - Suppr

Suppr

超能文献

Skin Hyperpigmentation in Coronavirus Disease 2019 Patients: Is Polymyxin B the Culprit?

作者信息

Lu Cuicui, Hou Ning

机构信息

Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.

出版信息

Front Pharmacol. 2020 Sep 3;11:01304. doi: 10.3389/fphar.2020.01304. eCollection 2020.

DOI:10.3389/fphar.2020.01304

PMID:33013367

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7494845/

Abstract

摘要

相似文献

Skin Hyperpigmentation in Coronavirus Disease 2019 Patients: Is Polymyxin B the Culprit?

Front Pharmacol. 2020 Sep 3;11:01304. doi: 10.3389/fphar.2020.01304. eCollection 2020.

Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process.

J Clin Pharm Ther. 2017 Oct;42(5):573-578. doi: 10.1111/jcpt.12543. Epub 2017 May 11.

Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review.

BMC Pharmacol Toxicol. 2018 Jul 4;19(1):41. doi: 10.1186/s40360-018-0226-1.

Polymyxin B-Induced Skin Hyperpigmentation.

Case Rep Med. 2020 Sep 18;2020:6461329. doi: 10.1155/2020/6461329. eCollection 2020.

Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study.

Pigment Cell Melanoma Res. 2016 May;29(3):388-90. doi: 10.1111/pcmr.12468. Epub 2016 Mar 17.

Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation.

Int J Antimicrob Agents. 2016 Nov;48(5):579-580. doi: 10.1016/j.ijantimicag.2016.08.010. Epub 2016 Sep 30.

Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B.

Clin Infect Dis. 2007 Jul 1;45(1):136-8. doi: 10.1086/518706.

Pigmentary mosaicism: a review of original literature and recommendations for future handling.

Orphanet J Rare Dis. 2018 Mar 5;13(1):39. doi: 10.1186/s13023-018-0778-6.

Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment.

J Clin Pharm Ther. 2019 Jun;44(3):415-419. doi: 10.1111/jcpt.12801. Epub 2019 Jan 21.

A newly formulated topical triple-antibiotic ointment minimizes scarring.

Cutis. 2000 Jun;65(6):401-4.

引用本文的文献

Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review.

Front Immunol. 2023 Feb 3;14:1074465. doi: 10.3389/fimmu.2023.1074465. eCollection 2023.

Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: A prospective study.

Front Pharmacol. 2022 Oct 13;13:1019411. doi: 10.3389/fphar.2022.1019411. eCollection 2022.

Integration of protein context improves protein-based COVID-19 patient stratification.

Clin Proteomics. 2022 Aug 11;19(1):31. doi: 10.1186/s12014-022-09370-0.

Proteomic Response Revealed Signaling Pathways Involving in the Mechanism of Polymyxin B-Induced Melanogenesis.

Microbiol Spectr. 2022 Apr 27;10(2):e0273021. doi: 10.1128/spectrum.02730-21. Epub 2022 Apr 4.

'COVID nose' - A unique post-COVID pigmentary sequelae reminiscing Chik sign: A descriptive case series.

J Eur Acad Dermatol Venereol. 2022 Jun;36(6):e419-e421. doi: 10.1111/jdv.17989. Epub 2022 Feb 16.

COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks.

Front Immunol. 2021 Oct 8;12:752380. doi: 10.3389/fimmu.2021.752380. eCollection 2021.

Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge.

J Med Virol. 2021 Oct;93(10):5756-5767. doi: 10.1002/jmv.27187. Epub 2021 Jul 16.

The Difference Between Polymyxin B and Polymyxin E in Causing Skin Hyerpigmentation.

Front Pharmacol. 2021 Apr 16;12:647564. doi: 10.3389/fphar.2021.647564. eCollection 2021.

本文引用的文献

Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature.

Dermatopathology (Basel). 2020 Jun 30;7(1):3-16. doi: 10.3390/dermatopathology7010002.

Acute kidney injury in critically ill patients with COVID-19.

Intensive Care Med. 2020 Jul;46(7):1339-1348. doi: 10.1007/s00134-020-06153-9. Epub 2020 Jun 12.

Management of acute kidney injury in patients with COVID-19.

Lancet Respir Med. 2020 Jul;8(7):738-742. doi: 10.1016/S2213-2600(20)30229-0. Epub 2020 May 14.

Is the kidney a target of SARS-CoV-2?

Am J Physiol Renal Physiol. 2020 Jun 1;318(6):F1454-F1462. doi: 10.1152/ajprenal.00160.2020. Epub 2020 May 15.

Polymyxin B-induced skin hyperpigmentation.

Transpl Infect Dis. 2020 Oct;22(5):e13312. doi: 10.1111/tid.13312. Epub 2020 May 27.

COVID-19 diagnosis and management: a comprehensive review.

J Intern Med. 2020 Aug;288(2):192-206. doi: 10.1111/joim.13091. Epub 2020 May 13.

Cutaneous manifestations in COVID-19: a first perspective.

J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213. doi: 10.1111/jdv.16387.

Clinical Characteristics of Coronavirus Disease 2019 in China.

N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.

Clinical Use of Polymyxin B.

Adv Exp Med Biol. 2019;1145:197-218. doi: 10.1007/978-3-030-16373-0_14.

Drug-Induced Hyperpigmentation: Review and Case Series.

J Am Board Fam Med. 2019 Jul-Aug;32(4):628-638. doi: 10.3122/jabfm.2019.04.180212.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Skin Hyperpigmentation in Coronavirus Disease 2019 Patients: Is Polymyxin B the Culprit?

Front Pharmacol. 2020 Sep 3;11:01304. doi: 10.3389/fphar.2020.01304. eCollection 2020.

Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process.

J Clin Pharm Ther. 2017 Oct;42(5):573-578. doi: 10.1111/jcpt.12543. Epub 2017 May 11.

Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review.

BMC Pharmacol Toxicol. 2018 Jul 4;19(1):41. doi: 10.1186/s40360-018-0226-1.

Polymyxin B-Induced Skin Hyperpigmentation.

Case Rep Med. 2020 Sep 18;2020:6461329. doi: 10.1155/2020/6461329. eCollection 2020.

Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study.

Pigment Cell Melanoma Res. 2016 May;29(3):388-90. doi: 10.1111/pcmr.12468. Epub 2016 Mar 17.

Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation.

Int J Antimicrob Agents. 2016 Nov;48(5):579-580. doi: 10.1016/j.ijantimicag.2016.08.010. Epub 2016 Sep 30.

Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B.

Clin Infect Dis. 2007 Jul 1;45(1):136-8. doi: 10.1086/518706.

Pigmentary mosaicism: a review of original literature and recommendations for future handling.

Orphanet J Rare Dis. 2018 Mar 5;13(1):39. doi: 10.1186/s13023-018-0778-6.

Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment.

J Clin Pharm Ther. 2019 Jun;44(3):415-419. doi: 10.1111/jcpt.12801. Epub 2019 Jan 21.

A newly formulated topical triple-antibiotic ointment minimizes scarring.

Cutis. 2000 Jun;65(6):401-4.

引用本文的文献

Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review.

Front Immunol. 2023 Feb 3;14:1074465. doi: 10.3389/fimmu.2023.1074465. eCollection 2023.

Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: A prospective study.

Front Pharmacol. 2022 Oct 13;13:1019411. doi: 10.3389/fphar.2022.1019411. eCollection 2022.

Integration of protein context improves protein-based COVID-19 patient stratification.

Clin Proteomics. 2022 Aug 11;19(1):31. doi: 10.1186/s12014-022-09370-0.

Proteomic Response Revealed Signaling Pathways Involving in the Mechanism of Polymyxin B-Induced Melanogenesis.

Microbiol Spectr. 2022 Apr 27;10(2):e0273021. doi: 10.1128/spectrum.02730-21. Epub 2022 Apr 4.

'COVID nose' - A unique post-COVID pigmentary sequelae reminiscing Chik sign: A descriptive case series.

J Eur Acad Dermatol Venereol. 2022 Jun;36(6):e419-e421. doi: 10.1111/jdv.17989. Epub 2022 Feb 16.

COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks.

Front Immunol. 2021 Oct 8;12:752380. doi: 10.3389/fimmu.2021.752380. eCollection 2021.

Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge.

J Med Virol. 2021 Oct;93(10):5756-5767. doi: 10.1002/jmv.27187. Epub 2021 Jul 16.

The Difference Between Polymyxin B and Polymyxin E in Causing Skin Hyerpigmentation.

Front Pharmacol. 2021 Apr 16;12:647564. doi: 10.3389/fphar.2021.647564. eCollection 2021.

本文引用的文献

Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature.

Dermatopathology (Basel). 2020 Jun 30;7(1):3-16. doi: 10.3390/dermatopathology7010002.

Acute kidney injury in critically ill patients with COVID-19.

Intensive Care Med. 2020 Jul;46(7):1339-1348. doi: 10.1007/s00134-020-06153-9. Epub 2020 Jun 12.

Management of acute kidney injury in patients with COVID-19.

Lancet Respir Med. 2020 Jul;8(7):738-742. doi: 10.1016/S2213-2600(20)30229-0. Epub 2020 May 14.

Is the kidney a target of SARS-CoV-2?

Am J Physiol Renal Physiol. 2020 Jun 1;318(6):F1454-F1462. doi: 10.1152/ajprenal.00160.2020. Epub 2020 May 15.

Polymyxin B-induced skin hyperpigmentation.

Transpl Infect Dis. 2020 Oct;22(5):e13312. doi: 10.1111/tid.13312. Epub 2020 May 27.

COVID-19 diagnosis and management: a comprehensive review.

J Intern Med. 2020 Aug;288(2):192-206. doi: 10.1111/joim.13091. Epub 2020 May 13.

Cutaneous manifestations in COVID-19: a first perspective.

J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213. doi: 10.1111/jdv.16387.

Clinical Characteristics of Coronavirus Disease 2019 in China.

N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.

Clinical Use of Polymyxin B.

Adv Exp Med Biol. 2019;1145:197-218. doi: 10.1007/978-3-030-16373-0_14.

Drug-Induced Hyperpigmentation: Review and Case Series.

J Am Board Fam Med. 2019 Jul-Aug;32(4):628-638. doi: 10.3122/jabfm.2019.04.180212.